MARKET

JUNS

JUNS

JUPITER NEUROSCIENCES, INC.
NASDAQ
0.3500
+0.0010
+0.29%
After Hours: 0.4000 +0.05 +14.29% 19:49 03/27 EDT
OPEN
0.3410
PREV CLOSE
0.3490
HIGH
0.4028
LOW
0.3140
VOLUME
168.53K
TURNOVER
--
52 WEEK HIGH
3.330
52 WEEK LOW
0.3140
MARKET CAP
12.05M
P/E (TTM)
-1.5244
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 6d ago
Weekly Report: what happened at JUNS last week (0316-0320)?
Weekly Report · 6d ago
Weekly Report: what happened at JUNS last week (0309-0313)?
Weekly Report · 03/16 09:15
Weekly Report: what happened at JUNS last week (0302-0306)?
Weekly Report · 03/09 09:15
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
Reuters · 03/02 13:02
Weekly Report: what happened at JUNS last week (0223-0227)?
Weekly Report · 03/02 09:15
Jupiter Neurosciences Receives Nasdaq Deficiency Notices, Faces Delisting
TipRanks · 02/27 22:25
Nasdaq Flags Jupiter Neurosciences for Bid Price and Market Value Listing Deficiencies
Reuters · 02/27 21:33
More
About JUNS
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.

Webull offers Jupiter Neurosciences Inc stock information, including NASDAQ: JUNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JUNS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JUNS stock methods without spending real money on the virtual paper trading platform.